Home › Calculator › KNTPF Dividend Calculator 2026
KNTPF Dividend DRIP Calculator 2026
841.04% YieldHealthcareKintor Pharmaceutical Limited · OTC
Price: $0.24 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When KNTPF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your KNTPF snowball 📈
$10,000 in KNTPF → $54462076.05M in 10 years · $4,056,221,590,640.55/month
About Kintor Pharmaceutical Limited (KNTPF) — Dividend Analysis 2026
Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally. The company's innovative pipeline features several key candidates, such as Proxalutamide, a next-generation androgen receptor (AR) antagonist currently being investigated for metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Another notable compound is Pyrilutamide, also an AR antagonist, designed to treat androgenetic alopecia (AGA) and acne vulgaris. Kintor also has an ALK-1 antibody in its portfolio, aimed at metastatic hepatocellular carcinoma (HCC) and various other solid tumors. Additionally, GT20029, a topical AR-PROTAC compound, is under development for AGA and acne vulgaris. A dual-target antibody, PD-L1/TGF-ß, is being explored for its potential in treating non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Further contributing to its diverse offerings is Detorsertib, intended for metastatic solid tumors including breast, prostate, and HCC. Finally, a Hedgehog/SMO Inhibitor, which targets the hedgehog signal transduction pathway, is being developed for blood cancer and basal-cell carcinoma. Established in 2009, Kintor Pharmaceutical Limited maintains its headquarters in Suzhou, People's Republic of China.
Compare KNTPF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full KNTPF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open KNTPF position with:
🌍 KNTPF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold KNTPF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 841.04% | 838.24% | $84,104 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 714.88% | 712.08% | $71,488 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 672.83% | 670.03% | $67,283 / yr |
| 🇬🇧 UK ISA | 0% | 841.04% | 838.24% | $84,104 / yr |
| 🇬🇧 UK Taxable | 8.75% | 767.45% | 764.65% | $76,745 / yr |
| 🇨🇦 TFSA | 0% | 841.04% | 838.24% | $84,104 / yr |
| 🇨🇦 CA Taxable | 25% | 630.78% | 627.98% | $63,078 / yr |
| 🇦🇺 Super (pension) | 15% | 714.88% | 712.08% | $71,488 / yr |
| 🇦🇺 AU Taxable | 30% | 588.73% | 585.93% | $58,873 / yr |
| 🇩🇪 DE Taxable | 26.375% | 619.22% | 616.42% | $61,922 / yr |
| 🇫🇷 FR Taxable | 30% | 588.73% | 585.93% | $58,873 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 KNTPF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 KNTPF Dividend Payment Schedule
KNTPF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 KNTPF vs Healthcare Benchmarks
How KNTPF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for KNTPF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ KNTPF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the KNTPF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Kintor Pharmaceutical Limited (KNTPF) is currently trading at $0.24, 98% below its 52-week high. The current dividend yield is 841.04% based on an annual payout of $2.00 per share.
KNTPF (Kintor Pharmaceutical Limited) — 841.04% Dividend Yield Analysis
Kintor Pharmaceutical Limited (KNTPF) is a healthcare stock currently trading at $0.24 with a dividend yield of 841.04%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (841.04%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.